This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Nektar Therapeutics Identifier:
First received: October 19, 2011
Last updated: August 8, 2017
Last verified: August 2017

The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102.

In addition the study will evaluate the safety of continued exposure to NKTR-102, observe disease status and survival status in subjects receiving NKTR-102, and evaluate the efficacy of NKTR-102 in subjects with advanced or metastatic solid tumors.

Condition Intervention Phase
Malignant Solid Tumor Drug: NKTR-102 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies

Further study details as provided by Nektar Therapeutics:

Primary Outcome Measures:
  • Safety [ Time Frame: Screening, Every 21 day cycle of treatment and Quarterly Follow-up ]
    Incidence and duration of toxicities, with severity grading

  • Disease Progression [ Time Frame: Screening, Every 21 day cycle of treatment and Quarterly Follow-up ]
    Disease progression and best response (per physician assessment)

Enrollment: 27
Actual Study Start Date: October 2011
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NKTR-102 Drug: NKTR-102
A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. Patients who previously received a dose of NKTR-102 < 145 mg/m2 will continue at the lower dose on this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  1. Received prior treatment with NKTR-102
  2. Free of disease progression since receiving NKTR-102
  3. Adequate bone marrow and organ function
  4. Treatment with NKTR-102 in the extension study to begin within 8 weeks after receipt of their of last dose of NKTR-102
  5. Agree to use adequate contraception


  1. Treatment with other anti-cancer therapy between the last dose of NKTR-102 in the prior study and before first dose of NKTR-102 in the extension study
  2. A toxicity that requires a 3rd dose reduction after taking NKTR-102 or are scheduled to receive a dose < 70 mg/m2 upon entry into this study
  3. Pregnancy or lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01457118

United States, California
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94143
Innovative Clinical Research Institute
Whittier, California, United States, 90603
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Ohio
University Hospital of Cleveland, Case Medical Center, Seidman Cancer Center
Cleveland, Ohio, United States, 44106
Institut Jules Bordet
Bruxelles, Belgium
CHU de Liege
Liege, Belgium, 4000
Sponsors and Collaborators
Nektar Therapeutics
Study Director: Ivan Gergel, MD Nektar Therapeutics
  More Information

Responsible Party: Nektar Therapeutics Identifier: NCT01457118     History of Changes
Other Study ID Numbers: 11-PIR-09
Study First Received: October 19, 2011
Last Updated: August 8, 2017

Keywords provided by Nektar Therapeutics:
Open Label multicenter extension study advanced solid tumors processed this record on September 19, 2017